Chromatin remodeling encompasses the ATP-dependent and enzymatic modifications that alter nucleosome positioning and chromatin structure, thereby regulating gene expression accessibility. These dynamic processes are essential for neuronal development, synaptic plasticity, learning, and memory. Dysregulated chromatin remodeling has emerged as a critical contributor to the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders.
| Mechanism | Enzyme Class | Function |
|---|---|---|
| Histone acetylation | HATs/HDACs | Relax chromatin |
| Histone methylation | HMTs/KDMs | Activate/repress |
| ATP-dependent | SWI/SNF, ISWI | Reposition nucleosomes |
| DNA methylation | DNMTs | Long-term silencing |
The ATP-dependent chromatin remodelers are a family of enzymes that use the energy of ATP hydrolysis to slide, eject, or restructure nucleosomes. These complexes are essential for regulating DNA accessibility in eukaryotic cells and play particularly crucial roles in post-mitotic neurons where chromatin plasticity underlies learning and memory formation[1].
The SWI/SNF (Switch/Sucrose Non-Fermentable) family of chromatin remodelers is evolutionarily conserved and essential for eukaryotic transcription regulation. In mammals, these complexes are called BAF (BRG1/BRM-associated factors) complexes and play critical roles in neuronal development, synaptic plasticity, and cognitive function[2].
Key complexes in neuronal function:
The BAF complexes exist in neuron-specific configurations. During neuronal development, there is a switch from progenitor-specific BAF53a-containing complexes to neuron-specific BAF53b-containing complexes, which are critical for synaptic plasticity and memory formation[4].
The Imitation SWI (ISWI) family of chromatin remodelers works in concert with histone chaperones to organize chromatin structure and regulate gene expression during development.
Chromodomain Helicase DNA-binding (CHD) proteins regulate transcription through chromatin remodeling and histone modification recruitment.
Histone post-translational modifications (PTMs) alter chromatin structure and gene expression patterns. The "histone code" hypothesis posits that combinations of modifications determine transcriptional outcomes[7].
Histone acetylation neutralizes the positive charge on lysine residues, loosening chromatin structure and promoting transcription. The balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) is critical for neuronal function.
Key findings in AD:
Key findings in PD:
Histone methylation can either activate or repress transcription depending on the residue modified:
Chromatin remodeling deficits in AD represent a fundamental molecular mechanism underlying cognitive decline. Multiple studies have demonstrated that epigenetic dysregulation precedes classic pathological hallmarks, suggesting chromatin changes may contribute to disease progression[13].
| Abnormality | Effect |
|---|---|
| H3K9 acetylation loss | Memory gene repression |
| HDAC2 overexpression | Synaptic plasticity impairment |
| BRG1 dysfunction | Inflammatory gene dysregulation |
| BAF250b reduction | Dendritic spine loss |
| H3K4me3 reduction | Transcriptional downregulation |
| H3K9me3 increase | Heterochromatin relaxation |
Key mechanisms:
Chromatin remodeling alterations in PD reflect the complex interplay between genetic susceptibility and environmental factors. Several PD-associated genes directly or indirectly affect chromatin states[17].
Mutant huntingtin disrupts chromatin regulation through multiple mechanisms, leading to widespread transcriptional dysregulation:
Chromatin dysregulation in ALS involves both genetic and sporadic forms, with TDP-43 pathology being a hallmark feature[22]:
Chromatin changes in ALS include:
FTD shares significant overlap with ALS in terms of chromatin dysregulation, particularly in cases with TDP-43 pathology[26]:
HDAC inhibitors represent the most advanced chromatin-targeting therapeutic strategy for neurodegeneration. Several compounds have progressed to clinical trials[27]:
| Compound | Target | Stage | Indication |
|---|---|---|---|
| Valproic acid | Class I/II HDACs | Phase III | AD, BD |
| Vorinostat | HDAC1/2/3/6 | Phase II | AD |
| Romidepsin | Class I HDACs | Phase I | PD |
| CI-994 | HDAC1 | Phase II | AD |
SIRT1 (Sirtuin 1) is an NAD+-dependent deacetylase with neuroprotective properties:
BRD4 inhibitors targeting the "-reader" proteins that recognize acetylated lysines represent an emerging therapeutic approach[30].
Viral delivery of chromatin remodelers or epigenetic modifiers:
HDAC6 is a unique HDAC isoform primarily located in the cytoplasm, where it deacetylates tubulin, HSP90, and other cytoplasmic proteins. Selective HDAC6 inhibition offers neuroprotection with potentially fewer side effects than broad-spectrum HDAC inhibitors[31]:
BET (Bromo and Extra-Terminal domain) proteins serve as readers of histone acetylation marks. BET inhibitors show therapeutic potential[32]:
Targeting the epigenetic mechanisms of aging represents a novel therapeutic approach[33]:
The epigenetic clock based on DNA methylation patterns provides a molecular measure of biological age. Accelerated epigenetic aging has been documented in:
Specific histone modification patterns serve as biomarkers:
The tricarboxylic acid (TCA) cycle intermediate α-ketoglutarate (α-KG) serves as a co-substrate for demethylases. Mitochondrial dysfunction in neurodegeneration reduces α-KG availability, leading to impaired demethylase activity and chromatin rigidity[37].
NAD+ decline with aging impairs sirtuin activity, affecting chromatin states and cellular stress responses. NAD+ replenishment strategies show promise in neurodegenerative disease models[38].
Metabolic state directly influences histone acetylation through acetyl-CoA availability. Glycolytic flux modulates H3K9 acetylation at metabolic gene promoters.
Several lncRNAs regulate chromatin states in neurodegeneration:
miRNAs modulate expression of chromatin remodelers:
The DNA damage response (DDR) is intimately linked to chromatin states, and this connection is particularly relevant in neurodegeneration where DNA repair is often compromised[40]:
Chronic neuroinflammation drives chromatin changes that contribute to neurodegeneration[41]:
The circadian clock intersects with chromatin regulation, and this connection is disrupted in neurodegeneration[42]:
Single-cell ATAC-seq and scRNA-seq integration will reveal cell-type-specific chromatin changes in neurodegenerative disease[44].
CRISPR-dCas9 fusion proteins enable precise epigenetic modifications:
Combining epigenomics with transcriptomics, proteomics, and metabolomics will provide comprehensive disease mechanism understanding.
Histone variants play crucial roles in chromatin dynamics and are differentially expressed in neurodegenerative diseases[^47]:
Alterations in nucleosome positioning contribute to transcriptional dysregulation:
Insulator proteins and boundary elements maintain proper chromatin architecture:
Three-dimensional chromatin organization is disrupted in neurodegenerative disease:
The REST (RE1 Silencing Transcription factor) complex is a master regulator of neuronal gene expression[^49]:
The Nucleosome Remodeling Deacetylase (NuRD) complex combines chromatin remodeling with HDAC activity[^50]:
NuRD complex alterations in neurodegeneration:
PRC1 and PRC2 mediate transcriptional repression through histone modifications[^51]:
Alterations in polycomb-mediated repression:
Emerging evidence shows sex-specific epigenetic alterations in neurodegeneration[^52]:
Distinguishing aging-related from disease-specific chromatin changes is critical[^53]:
The difference between chronological and epigenetic age (epigenetic clock) provides diagnostic information[^54]:
In neurodegeneration:
Peripheral blood offers accessible epigenetic markers[^55]:
Several novel HDAC-targeted compounds in development[^56]:
BET protein inhibitors represent a growing therapeutic class[^57]:
Direct targeting of chromatin remodelers[^58]:
Wilson et al. ATP-dependent chromatin remodelers in the nervous system (2010). 2010. ↩︎
Kadoch et al. Proteomics of SWI/SNF complexes reveal disease relevance (2016). 2016. ↩︎
Mandel et al. ARID1B mutations in neurodevelopmental disorders (2016). 2016. ↩︎
Hsieh et al. Activity-dependent BAF53b function in synaptic plasticity (2014). 2014. ↩︎
Yang et al. SMARCA5 deficiency and progressive neurodegeneration (2016). 2016. ↩︎
Potts et al. CHD5 in nervous system development (2011). 2011. ↩︎
Strahl et al. The histone code and its extensions (2000). 2000. ↩︎
Graff et al. Histone acetylation deficits in AD (2012). 2012. ↩︎
Yamaguchi et al. HDAC2 in synaptic plasticity and memory (2013). 2013. ↩︎
Cook et al. HDAC6 inhibition in tauopathy models (2014). 2014. ↩︎
Sundaram et al. Alpha-synuclein and chromatin (2015). 2015. ↩︎
Zhang et al. PINK1 promoter methylation in PD (2015). 2015. ↩︎
Coppola-Schaum, Epigenetic dysregulation in AD (2021). 2021. ↩︎
Fischer et al. HDAC inhibitor improves memory in mice (2007). 2007. ↩︎
Donmez et al. SIRT1 and neurodegeneration (2012). 2012. ↩︎
Frost et al. Tau affects transcriptional networks (2014). 2014. ↩︎
Klein et al. LRRK2 and chromatin regulation (2019). 2019. ↩︎
Surguchov et al. Synuclein and chromatin remodelers (2021). 2021. ↩︎
Gao et al. PINK1 and epigenetic regulation (2017). 2017. ↩︎
Holly et al. Huntingtin and BAF complexes (2013). 2013. ↩︎
Thomas et al. HDAC inhibitors in HD models (2008). 2008. ↩︎
Rohan et al. TDP-43 chromatin regulation in ALS (2020). 2020. ↩︎
Chen-Plotkin et al. TDP-43 in ALS and FTD (2012). 2012. ↩︎
D'Amico et al. FUS and chromatin in ALS (2019). 2019. ↩︎
McGregor et al. C9orf72 DNA methylation in ALS/FTD (2020). 2020. ↩︎
Chang et al. Chromatin dysregulation in FTD (2021). 2021. ↩︎
Brunet et al. HDAC inhibitors in clinical trials (2020). 2020. ↩︎
Sawda et al. Resveratrol and neurodegenerative disease (2017). 2017. ↩︎
Mercken et al. SRT2104 development for AD (2014). 2014. ↩︎
Boehm et al. Bromodomain inhibitors in neurodegeneration (2020). 2020. ↩︎
Simmons et al. HDAC6-selective inhibitors in AD (2021). 2021. ↩︎
Melo et al. BET inhibitors in neurodegeneration (2021). 2021. ↩︎
Feser et al. Epigenetic clock reversal strategies (2020). 2020. ↩︎
Horvath et al. Epigenetic clock in AD brain (2015). 2015. ↩︎
Horvath et al. Epigenetic clock in PD (2018). 2018. ↩︎
Horvath et al. Accelerated epigenetic aging in HD (2016). 2016. ↩︎
Kaelin et al. α-Ketoglutarate and epigenetics (2012). 2012. ↩︎
Imai et al. NAD+ and sirtuins in aging (2014). 2014. ↩︎
Spreafico et al. NEAT1 in AD (2020). 2020. ↩︎
Madabhushi et al. DNA damage and chromatin in neurons (2015). 2015. ↩︎
Cruchaga et al. Neuroinflammation and epigenetics (2022). 2022. ↩︎
Chen et al. Circadian chromatin regulation (2021). 2021. ↩︎
Kandel et al. HDAC2 and memory formation (2013). 2013. ↩︎
Kwart et al. Single-cell epigenomics in neurodegeneration (2019). 2019. ↩︎